A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants
Clinical trial NCT01745120 · COMPLETED
Trial details
- NCT number
- NCT01745120
- Sponsor
- Genetix Biotherapeutics Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-01
- Primary completion
- 2018-02-08
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.